Peter Wust1, Marcus Beck1, Robert Dabrowski1, Oliver Neumann1, Sebastian Zschaeck1,2, David Kaul1, Dominik P Modest3, Carmen Stromberger1, Bernhard Gebauer4, Pirus Ghadjar5. 1. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Radiation Oncology, Augustenburger Platz 1, 13353, Berlin, Germany. 2. Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Straße 2, 10178, Berlin, Germany. 3. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Medical Oncology, Berlin, Germany. 4. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Radiology, Berlin, Germany. 5. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Radiation Oncology, Augustenburger Platz 1, 13353, Berlin, Germany. pirus.ghadjar@charite.de.
Abstract
BACKGROUND: Several radiotherapeutic approaches for patients with oligotopic malignant liver lesions unfit for surgical resection exist. The most advanced competitive techniques are high-dose-rate (HDR) brachytherapy, Cyberknife, volume-modulated-arc therapy (VMAT) and Tomotherapy. We evaluated the optimal technique by a planning study for a single ablative dose with different lesion sizes. METHODS: We compared dose distributions of HDR-brachytherapy with stereotactic ablative radiotherapy using the Cyberknife, VMAT or Tomotherapy. Tumor-control-probabilities (TCP), normal-tissue-complication-probabilities (NTCP) were determined in a theoretical framework applying a single dose of 20 Gy (demanding 95% coverage) for intrahepatic lesions of 1-5 cm in size. We evaluated therapeutic ratios by TCP (mean dose in the lesion) relative to high-dose (conformality) or low-dose liver exposition in dependency on the lesion size for each technique. In addition, we considered treatment times and accuracy (clinical target volume vs planning target volume). RESULTS: HDR-brachtherapy has the highest therapeutic ratios with respect to high-dose as well as low-dose liver exposition even for extended lesions, and the Cyberknife being suited second best. However, for lesions ≥ 3 cm diameter the therapeutic ratios of all ablative techniques are increasingly converging, and better tolerance and shorter treatment times of noninvasive external techniques become more important. On the other hand, mean tumor doses of HDR-brachytherapy of near 60 Gy are unattainable by the other techniques gaining only 22-34 Gy, and the conformality of HDR-brachytherapy is still rather good for lesions ≥ 3 cm diameter. CONCLUSIONS: HDR-brachytherapy is by far the most effective technique to treat intrahepatic lesions by a single fraction, but sparing of the surroundings declines with increasing lesion size and approaches the benchmarks of external beam radiosurgery techniques. External beam radiotherapy has the advantage to use suitable fractionation schedules.
BACKGROUND: Several radiotherapeutic approaches for patients with oligotopic malignant liver lesions unfit for surgical resection exist. The most advanced competitive techniques are high-dose-rate (HDR) brachytherapy, Cyberknife, volume-modulated-arc therapy (VMAT) and Tomotherapy. We evaluated the optimal technique by a planning study for a single ablative dose with different lesion sizes. METHODS: We compared dose distributions of HDR-brachytherapy with stereotactic ablative radiotherapy using the Cyberknife, VMAT or Tomotherapy. Tumor-control-probabilities (TCP), normal-tissue-complication-probabilities (NTCP) were determined in a theoretical framework applying a single dose of 20 Gy (demanding 95% coverage) for intrahepatic lesions of 1-5 cm in size. We evaluated therapeutic ratios by TCP (mean dose in the lesion) relative to high-dose (conformality) or low-dose liver exposition in dependency on the lesion size for each technique. In addition, we considered treatment times and accuracy (clinical target volume vs planning target volume). RESULTS: HDR-brachtherapy has the highest therapeutic ratios with respect to high-dose as well as low-dose liver exposition even for extended lesions, and the Cyberknife being suited second best. However, for lesions ≥ 3 cm diameter the therapeutic ratios of all ablative techniques are increasingly converging, and better tolerance and shorter treatment times of noninvasive external techniques become more important. On the other hand, mean tumor doses of HDR-brachytherapy of near 60 Gy are unattainable by the other techniques gaining only 22-34 Gy, and the conformality of HDR-brachytherapy is still rather good for lesions ≥ 3 cm diameter. CONCLUSIONS: HDR-brachytherapy is by far the most effective technique to treat intrahepatic lesions by a single fraction, but sparing of the surroundings declines with increasing lesion size and approaches the benchmarks of external beam radiosurgery techniques. External beam radiotherapy has the advantage to use suitable fractionation schedules.
Authors: B Emami; J Lyman; A Brown; L Coia; M Goitein; J E Munzenrider; B Shank; L J Solin; M Wesson Journal: Int J Radiat Oncol Biol Phys Date: 1991-05-15 Impact factor: 7.038
Authors: Charlie C Pan; Brian D Kavanagh; Laura A Dawson; X Allen Li; Shiva K Das; Moyed Miften; Randall K Ten Haken Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Jens Ricke; Konrad Mohnike; Maciej Pech; Max Seidensticker; Ricarda Rühl; Gero Wieners; Gunnar Gaffke; Siegfried Kropf; Roland Felix; Peter Wust Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-19 Impact factor: 7.038
Authors: E J A Morris; D Forman; J D Thomas; P Quirke; E F Taylor; L Fairley; B Cottier; G Poston Journal: Br J Surg Date: 2010-07 Impact factor: 6.939
Authors: Jens Ricke; Peter Wust; Anna Stohlmann; Alexander Beck; Chie Hee Cho; Maciej Pech; Gero Wieners; Birgit Spors; Michael Werk; Christian Rosner; Enrique Lopez Hänninen; Roland Felix Journal: Strahlenther Onkol Date: 2004-05 Impact factor: 3.621
Authors: Davide Scafa; Thomas Muedder; Jasmin A Holz; David Koch; Younéss Nour; Stephan Garbe; Maria A Gonzalez-Carmona; Georg Feldmann; Tim O Vilz; Mümtaz Köksal; Frank A Giordano; Leonard Christopher Schmeel; Gustavo R Sarria Journal: Front Oncol Date: 2021-12-02 Impact factor: 6.244